Pathogenesis of Glomerulosclerosis Description: The aim of this study is to determine whether the addition of novel sodium glucose cotransport-2 inhibitors (SGLT2i) to standard of care leads to reduced intraglomerular pressure and suppression of proteinuria, with a further goal of examining mechanisms of SGLT2 inhibition by measuring renal hemodynamic function and sodium handling Trial Summary: Condition-AIDS Associated Nephropathy -Focal Glomerulosclerosis -HIV Infections Start DateApril 1994 NCT IDNCT00001392 Study TypeObservational Eligibility: Age4 years and older Accepts Healthy VolunteersYes Inclusion Criteria: An unlimited number of subjects with known or suspected glomerular or tubulointerstitial disease will be eligible for study. No sex, race or ethnic selection will be applied. Frequently Asked Questions (FAQs): This study is listed as an observational study. What does that mean? An observational study is a study attempting to find a cause-effect relationship. For this study, researchers will attempt to learn more about the pathogenesis of glomerulosclerosis. What would I/my child have to do if enrolled in this study? Selected subjects will be invited to provide informed consent to undergo a kidney biopsy for research purposes. Blood, urine, and tissue samples will be evaluated both for standard diagnostic purposes and for research purposes. Who can participate? Children and adults 4 years or older with known or suspected glomerular or tubulointerstitial disease. Who do I contact with general questions? Please call or email Jessica M. Warren at (301) 451-9946 or jessica.warren@mail.nih.gov respectively with any questions. Where can I learn more? Pathogenesis of Glomerulosclerosis Where can I participate? The following is a list of Pathogenesis of Glomerulosclerosis site locations: Contact Information by Trial Site StateCitySite NameContact Information MDBethesdaNational Institutes of Health Clinical CenterJessica M. Warren: (301) 451-9946, jessica.warren@nih.gov Search for more clinical trials